U.S. markets closed

Verve Therapeutics, Inc. (VERV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.69+0.34 (+2.08%)
At close: 04:00PM EDT
16.50 -0.19 (-1.14%)
After hours: 05:56PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close16.35
Bid16.45 x 1200
Ask17.50 x 800
Day's Range16.37 - 17.06
52 Week Range10.70 - 43.00
Avg. Volume713,649
Market Cap1.06B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VERV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Verve Therapeutics, Inc.
    ARWR: Lowering target price to $26.00ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $26.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • Simply Wall St.

    Verve Therapeutics (NASDAQ:VERV) shareholders are up 4.6% this past week, but still in the red over the last year

    Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...

  • Motley Fool

    3 Deeply Undervalued Stocks That Could Double Your Money

    Growth stocks had an exceptionally rough 2022. Supply chain woes, sky-high inflation, rising interest rates, and the conflict in Ukraine all conspired last year to spur a major correction across the growth equity landscape. In turn, Wall Street analysts think there are some tremendous bargains within this space right now.

  • TipRanks

    2 High-Risk, High-Reward Stock Bets Cathie Wood Is Taking Into 2023

    The tech-heavy Nasdaq represents a collection of more risky stocks than the other major indexes and that is reflected by a poorer performance in bear markets and a better display during bull runs. But the risks associated with the Nasdaq are mere child play compared to edgier funds such as Cathie Wood’s Ark Innovation ETF. Now that really hit the skids during last year’s bear, but the fund is also up 37% year-to-date, putting the Nasdaq's 15% gain in the shade. In fact, throwing more shade the N